{
    "organizations": [],
    "uuid": "b3891593d9d5504e924addb8ca3e72ec9002045f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-merck-co-says-keytruda-phase-3-key/brief-merck-co-says-keytruda-phase-3-keynote-189-trial-met-its-dual-primary-endpoints-idUSFWN1PB0LH",
    "ord_in_thread": 0,
    "title": "BRIEF-Merck & Co Says Keytruda Phase 3 Keynote-189 Trial Met Its Dual Primary Endpoints",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Merck & Co Inc:\n* MERCK‘S KEYTRUDA(R) (PEMBROLIZUMAB) SIGNIFICANTLY IMPROVED OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AS FIRST-LINE TREATMENT IN COMBINATION WITH PEMETREXED AND PLATINUM CHEMOTHERAPY FOR PATIENTS WITH METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER (KEYNOTE-189)\n* MERCK & CO INC - PIVOTAL PHASE 3 KEYNOTE-189 TRIAL MET ITS DUAL PRIMARY ENDPOINTS\n* MERCK & CO INC - ‍SAFETY PROFILE OF KEYTRUDA IN COMBINATION WAS CONSISTENT WITH THAT PREVIOUSLY OBSERVED​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T20:35:00.000+02:00",
    "crawled": "2018-01-17T19:46:48.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "merck",
        "co",
        "inc",
        "merck",
        "keytruda",
        "r",
        "pembrolizumab",
        "significantly",
        "improved",
        "overall",
        "survival",
        "survival",
        "treatment",
        "combination",
        "pemetrexed",
        "platinum",
        "chemotherapy",
        "patient",
        "metastatic",
        "nonsquamous",
        "cell",
        "lung",
        "cancer",
        "merck",
        "co",
        "inc",
        "pivotal",
        "phase",
        "trial",
        "met",
        "dual",
        "primary",
        "endpoint",
        "merck",
        "co",
        "inc",
        "profile",
        "keytruda",
        "combination",
        "consistent",
        "previously",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}